Blood
Articles in this Issue
Babesiosis precipitating immune thrombotic thrombocytopenic purpura
Domain and residue mapping of autoantibodies to β2GPI reveals differences among antiphospholipid syndrome phenotypes
Abstract Antiphospholipid antibodies targeting β2-glycoprotein I (β2GPI) are a hallmark of antiphospholipid syndrome (APS), associated with an increased risk of thrombosis and preg...
CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia
Abstract Success of chimeric antigen receptor (CAR) T-cell therapy in lymphoid malignancies has not yet been recapitulated in acute myeloid leukemia (AML). We developed CAR T cells...
Asquith NL, Carminita E, Camacho V, et al. The bone marrow is the primary site of thrombopoiesis. <i>Blood</i> . 2024;143(3):272-278.
Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody
Abstract The recent approval of adeno-associated virus (AAV)–based gene therapies for hemophilia A (HA) represents a major advancement in the management of this X-linked bleeding d...
Runx2 takes center stage in regulating HSC expansion
LEF1 and CLL: a matter of quantity and quality
NMNAT3 deficiency: a novel red blood cell enzymopathy causing hemolysis by altering NAD levels and glycolysis
Abstract We describe, to our knowledge, the first case of nicotinamide mononucleotide adenylyl transferase 3 (NMNAT3) deficiency, a novel red cell enzymopathy that causes reduced N...
Armed and SAVVY: CAR T cells combat AML
Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at <i>CDH22</i> / <i>CD40</i>
Abstract To identify genetic variants that influence myeloproliferative neoplasm (MPN) phenotypes, we undertook a 2-stage patient-only genome-wide association study. MPN subtypes (...
Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial
Abstract Because frail patients and patients aged ≥80 years with chronic lymphocytic leukemia (CLL) are still underrepresented in clinical trials, the CLL-Frail trial aimed to eval...
Silkenstedt E, Dreyling M. Treatment of relapsed/refractory MCL. <i>Blood</i> . 2025;145(7):673-682.
Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?
Abstract Classic Hodgkin lymphoma (cHL) is highly curable with risk-adapted first-line treatment. Due to exceptional efficacy, antiprogrammed cell death protein 1 antibodies (aPD1)...
Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia
Abstract The transcription factor lymphoid enhancer-binding factor 1 (LEF1) is aberrantly expressed across all subtypes and stages of chronic lymphocytic leukemia (CLL), yet the mo...
MPN predisposition: shared roots, split branches
Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody
Abstract Immune-driven fibrotic skin diseases, including scleroderma/systemic sclerosis (SSc) and chronic graft-versus-host disease (GVHD), cause skin stiffening that has a major i...
Beyond Arg39: new insights into antiphospholipid antibodies
Acalabrutinib to assail CLL in the frail
New approach targets key traffickers in the fibrosis network
Matchmaking gene therapy with mimetic antibodies
A genome-wide screen identifies <i>Runx2</i> as a novel regulator of hematopoietic stem cell expansion and T-cell commitment
Abstract Self-renewing multipotent hematopoietic stem cells (HSCs) are a rare but important cell population that can reconstitute the entire blood and immune system after transplan...